Job Watch

Innovation Corps (I-Corps) at NIH Program for NIH and CDC Translational Research (Admin Supp Clinical Trial NOT Allowed)

Funding Opportunity PA-25-212 from the NIH Guide for Grants and Contracts. Through this I-Corps at NIH program Notice of Funding Opportunity (NOFO), NIH and CDC provide administrative supplement awards to active SBIR (NIH and CDC) and STTR Phase I (NIH only) grantees/awardees. The I-Corps at NIH mission is to empower entrepreneurs in developing and validating a strategic business model through diverse customer discovery in order to meet unmet clinical needs. I-Corps enables and accelerates the transformation of invention to impact SBIR and STTR Phase I awardees in a no-cost extension are eligible as long as, if selected, their no cost extension covers the entire duration of I-Corps at NIH cohort. The program provides three-member project teams with access to instruction and mentoring to accelerate the translation of technologies currently being developed with NIH and CDC SBIR and STTR funding. It is anticipated that outcomes for the I-Corps teams participating in this program will include significantly refined commercialization plans and well-informed pivots in their overall commercialization strategies. Prospective applicants are strongly encouraged to contact Scientific/Research staff for more information about the program before applying.

Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed)

Funding Opportunity PAR-25-059 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) encourages research grant applications to develop in vitro and/or ex vivo assays and conduct iterative screening efforts to identify and characterize potential therapeutic agents for neurological or neuromuscular disorders. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the Blueprint Neurotherapeutics Network (BPN) or other translational programs.

Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)

Funding Opportunity PAR-25-058 from the NIH Guide for Grants and Contracts. Reissue PAR-21-122. This NOFO provides funding to conduct pharmacodynamic, pharmacokinetic, and in vivo efficacy studies to demonstrate that proposed therapeutic agent(s) have sufficient biological activity to warrant further development to treat neurological or neuromuscular disorders that fall under the NINDS mission. Therapeutic agents include small molecules, biologics or biotechnology-derived products. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the Blueprint Neurotherapeutics Network or other translational programs.

Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed)

Funding Opportunity PAR-25-060 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) encourages the development and validation of animal models and human/animal tissue ex vivo systems that recapitulate the phenotypic and physiologic characteristics of a defined neurological or neuromuscular disorder. The goal of this FOA is to promote a significant improvement in the translational relevance of animal models or ex vivo systems that will be utilized to facilitate future development of neurotherapeutics. Ideally, models proposed for this FOA would have the potential to provide feasible and meaningful assessments of efficacy following therapeutic intervention that would be applicable in both preclinical and clinical settings. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) Program focused on enabling the exploratory and early stages of drug discovery.

Asklepios BioPharmaceutical, Inc.: Bioinformatician

New Scientist - Bioinformatics - Mon, 2024-10-21 20:00
Competitive: Asklepios BioPharmaceutical, Inc.: Asklepios BioPharmaceutical, Inc. (AskBio) is a leading, clinical-stage gene therapy company founded in 2001 based on the work of adeno-associated vir Edinburgh, City of Edinburgh, United Kingdom
Categories: Job Watch

Environmental Health Disparities Centers (P50) Clinical Trial Optional

Funding Opportunity RFA-MD-24-010 from the NIH Guide for Grants and Contracts. The Environmental Health Disparities Centers seeks to solicit multidisciplinary research, research capacity building, and community-engaged research activities on environmental health disparities and environmental justice research for populations and communities experiencing health disparities within the US and its territories.

King's College London: Postdoctoral Research Associate in Systems Medicine

New Scientist - Bioinformatics - Sat, 2024-10-19 20:00
Competitive: King's College London: About Us King's College London is one of the world's leading research universities, renowned for its excellence in education, groundbreaking researc London, United Kingdom
Categories: Job Watch

TMD Collaborative for IMproving PAtient-Centered Translational Research (TMD IMPACT) (U54 Clinical Trial Optional)

Funding Opportunity RFA-DE-25-003 from the NIH Guide for Grants and Contracts. To develop a national, interdisciplinary, patient-centered research consortium to advance Temporomandibular Disorders (TMDs) basic and clinical research, research training, and translation to evidence-based treatments and improved clinical care.

Co-infection and Cancer (R01 Clinical Trial Not Allowed)

Funding Opportunity PAR-25-082 from the NIH Guide for Grants and Contracts. This initiative seeks to enhance our mechanistic and epidemiologic understanding of infection-related cancers, with a focus on the etiologic roles of co-infection in cancer. Preference will be given to co-infections (excluding co-infection with human immunodeficiency virus [HIV]) that engendered novel opportunities for prevention and treatment and focus on understudied populations. Coinfection is defined as the occurrence of infections by two or more infectious (pathogenic or nonpathogenic) agents either concurrently or sequentially and includes both acute and chronic infections by viruses, bacteria, parasites, and/or other microorganisms.

Pages

Subscribe to Anil Jegga aggregator - Job Watch